Creative Medical up on positive data for pain treatment procedure

Creative Medical Technology Holdings

18/05/2023 13:51

** Shares of biotech co Creative Medical Technology Holdings
Inc  CELZ.O  up 8.3% at $0.72 premarket 
    ** Co reports positive topline pilot study data for its
StemSpine procedure that showed significant efficacy in chronic
lower back pain treatment 
    ** StemSpine is a patented, ultrasound-guided, non-surgical
procedure that utilizes a patient's own bone marrow aspirate for
the treatment of chronic lower back pain
    ** CELZ says none of the patients required re-dosage or
surgical intervention at the primary goal of six months and
there were no safety-related concerns 
    ** The procedure showed greater than 90% reduction in
narcotic usage, greater than 80% reduction in pain score - CELZ
    ** Co also adds that the procedure showed a greater than 50%
reduction on a scale used to quantify disability for low back
pain  
    ** As of last close, co's stock up 73.2% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))